Sanofi, Selecta sign allergy immunotherapy deal worth up to $900M

11/29/2012 | Genetic Engineering & Biotechnology News · Reuters

Sanofi agreed to use Selecta Biosciences' vaccine technology to develop one immunotherapy for a life-threatening food allergy, with an option to develop two more treatments. The deal entitles Selecta to as much as $300 million in preclinical, clinical, regulatory and sales milestone payments for each allergen indication, for as many as three immunotherapy candidates, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX